Clinical Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
Status:
Completed
Trial end date:
2021-08-10
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of KHK7791 by comparing changes in serum phosphorus levels from
baseline values between hemodialysis patients with hyperphosphatemia receiving repeated
administration of KHK7791 for 8 weeks and those receiving placebo.